Scarica l'app Stockscreener
2.76
32.35%
-1.32
Dopo l'orario di chiusura:
2.75
-0.010
-0.36%
Elicio Therapeutics Inc Borsa (ELTX) Ultime notizie
Elicio shares slide after pancreatic cancer vaccine falls short in mid-stage study - whbl.com
Elicio Confident In Phase III Plan Despite Phase II Miss In Pancreatic Cancer - Citeline News & Insights
Do phase II data Amplify KRAS PDAC promise for Elicio? - BioWorld News
ELTX Stock Heads For Worst Day Ever — Elicio Therapeutics' Pancreatic Cancer Data Disappoints - Yahoo Finance
Top Midday Decliners - Moomoo
ELTX Maintained by HC Wainwright & Co. -- Price Target Raised to $23 - GuruFocus
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Elicio Therapeutics Pancreatic Cancer Study Disappoints - Benzinga
ELTX INVESTOR ALERT: Holzer & Holzer, LLC Investigation of Elicio Therapeutics, Inc. - GlobeNewswire
Elicio nosedives on phase 2 data for pancreatic cancer asset (ELTX:NASDAQ) - Seeking Alpha
Elicio crashes on Phase II miss for cancer vaccine, pins hopes on post-hoc signal - FirstWord PHARMA
Elicio Therapeutics reports Phase 2 AMPLIFY-7P results - grafa.com
Elicio Thera tanks on disappointing Phase II AMPLIFY-7P study - The Pharma Letter
Rodman & Renshaw raises Elicio Therapeutics price target to $17.50 By Investing.com - Investing.com Canada
H.C. Wainwright reiterates Elicio Therapeutics stock rating at buy - Investing.com
Elicio crashes on midstage pancreatic cancer miss but will advance to Phase 3 - BioSpace
Why is Elicio Therapeutics stock collapsing today? By Investing.com - Investing.com Canada
Why is Elicio Therapeutics stock collapsing today? - Investing.com
Elicio shares tumble after pancreatic cancer therapy misses mid-stage study goal - marketscreener.com
Elicio Therapeutics Reports Phase 2 AMPLIFY-7P Results and Refines Phase 3 Strategy for ELI-002 7P in Adjuvant Pancreatic Cancer – Minichart - Minichart
Elicio Unveils Phase 2 ELI-002 Results and Phase 3 Plan - TipRanks
Elicio’s pancreatic cancer trial misses primary endpoint By Investing.com - Investing.com South Africa
Elicio Therapeutics Shares Plunge After Pancreatic Cancer Study Misses Main Goal (ELTX) - Yahoo Finance
Elicio’s pancreatic cancer trial misses primary endpoint - Investing.com UK
Elicio (Nasdaq: ELTX) Phase 2 ELI-002 refocuses on R0 patients - Stock Titan
Elicio Therapeutics price target raised to $23 from $17 at H.C. Wainwright - TipRanks
Elicio Therapeutics stock tumbles after trial misses endpoint By Investing.com - Investing.com South Africa
Elicio Therapeutics stock tumbles after trial misses endpoint - Investing.com
Elicio Therapeutics Reports Results From Phase 2 AMPLIFY-7P Study And Outlines Refined Phase 3 Development Strategy For ELI-002 7P In Adjuvant Pancreatic Cancer - TradingView
Pancreatic cancer trial finds DFS gain in surgery patients, Phase 3 planned - Stock Titan
Elicio Therapeutics Price Target Announced at $27.00/Share by B. Riley Securities - Moomoo
(ELTX) Risk Channels and Responsive Allocation - Stock Traders Daily
B. Riley Initiates Elicio Therapeutics at Buy With $27 Price Target - marketscreener.com
Elicio Therapeutics (ELTX) Falls 4.8% as Biotech Volatility Persists — Key Support in FocusOn Balance Volume - newsline.com
ELTX Stock Price, Quote & Chart | ELICIO THERAPEUTICS INC (NASDAQ:ELTX) - ChartMill
Elicio Therapeutics Announces Publication in Peer-Reviewed - GlobeNewswire
Elicio cancer immunotherapy triggers months-long immune memory in animals - Stock Titan
(ELTX) Movement as an Input in Quant Signal Sets - Stock Traders Daily
ELTX Reiterates by HC Wainwright & Co. -- Price Target Maintained at $17 - GuruFocus
H.C. Wainwright Maintains Elicio Therapeutics(ELTX.US) With Buy Rating, Maintains Target Price $17 - Moomoo
Elicio Therapeutics (ELTX) Holds Near Resistance as Therapeutic Pipeline Momentum BuildsAD Line Divergence - newsline.com
Elicio Therapeutics (ELTX) Climbs +8.72% — Resistance at $10.47 in Focus 2026-05-20Leveraged ETF Flow - The Legal Advocate
Elicio Therapeutics (ELTX) Q1 2026 Earnings Miss: EPS $-0.65 vs $-0.47 ExpectedEPS Consistency Score - The Legal Advocate
Liquidity Mapping Around (ELTX) Price Events - Stock Traders Daily
MIT: Big strides in cancer detection and treatment from the tiniest technologies - marketscreener.com
TradingKey - TradingKey
Elicio Therapeutics | 10-Q: Q1 2026 Earnings Report - Moomoo
JonesTrading Maintains Elicio Therapeutics(ELTX.US) With Buy Rating, Maintains Target Price $18 - Moomoo
Elicio Therapeutics (NASDAQ:ELTX) Q1 2026 Results Show Extended Cash Runway Ahead of Key Phase 2 Data Readout - ChartMill
Elicio Therapeutics, Inc. 1Q 2026: Net income $(11.8M), EPS $(0.65) — 10-Q Summary - TradingView
Elicio Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updates - The Manila Times
Elicio Therapeutics: Q1 Earnings Snapshot - marketscreener.com
Elicio Therapeutics (NASDAQ: ELTX) warns on going concern as cash runs to Q4 2026 - Stock Titan
Elicio Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Elicio Therapeutics (Nasdaq: ELTX) posts Q1 loss and extends cash runway - Stock Titan
What you need to know before buying Elicio Therapeutics (ELTX) (-1.00%) 2026-05-08Trending Stock Ideas - newser.com
Elicio Therapeutics Inc expected to post a loss of 46 cents a shareEarnings Preview - TradingView
Why (ELTX) Price Action Is Critical for Tactical Trading - Stock Traders Daily
The one number that tells Elicio Therapeutics (ELTX) whole earnings story | Q4 2025: Earnings Beat EstimatesTurnaround Phase - newser.com
Elicio Therapeutics (ELTX) narrowly tops Q4 2025 EPS estimates, shares rise nearly 3 percent in today’s trading. - The Legal Advocate
Elicio Therapeutics to Present at the Bank of America Healthcare Conference - The Manila Times
Elicio Therapeutics lines up May 14 investor webcast in Las Vegas - Stock Titan
elicio-ex311to10xk_aapri.htm - SEC.gov
elicio-ex312to10xk_aapri.htm - SEC.gov
1.27%
1.43%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):